Non-Invasive Prenatal Testing (NIPT) is a powerful tool in modern prenatal care. This guide explains the numbers behind the science, so you can feel confident in what your results mean.
Chat with our Genetic Counsellor, receive your at-home DNA kit with a quick cheek swab, send it back, and get your results in under 4 weeks.
NIPT doesn’t give a simple “yes” or “no” answer. It looks at tiny fragments of your baby’s DNA in your blood and calculates the chance of certain genetic conditions. We compare your results to data from thousands of other pregnancies, using terms like sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). These numbers help us understand how likely it is that a result is correct and help you make informed decisions.
We offer expert advice and testing for a range of genes that may increase your risk of developing certain types of cancer.
View Full Gene List
Explore NIPTs and compare the conditions they screen for, plus their sensitivity, specificity, PPV, and NPV.*
| Condition | Prelavence |
PrenatalSafe Complete Plus
|
PrenatalSafe 3UK
|
KNOVA
|
Unity Aneuploidies
|
Unity Complete
|
Panorama AI
|
Panorama Microdeletions
|
|||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sens | Spec | PPV | NPV | Sens | Spec | PPV | NPV | Sens | Spec | PPV | NPV | Sens | Spec | PPV | NPV | Sens | Spec | PPV | NPV | Sens | Spec | PPV | NPV | Sens | Spec | PPV | NPV | ||
| Autosomal Aneuploidies | |||||||||||||||||||||||||||||
| Trisomy 21 (Down Syndrome) | 1:700 | 99.54% | 100% | 90.9% | >99.99% | 99.54% | 100% | - | - | 97.8% | 99.4% | 93.7% | 99.8% | 99.7% | 99.7% | 90.5% | >99.9% | 99.7% | 99.7% | 90.5% | >99.9% | 99.0% | >99% | 95% | >99.99% | 99.0% | >99% | 95% | >99.99% |
| Trisomy 18 (Edwards Syndrome) | 1:5,000 | 100% | 100% | 97.6% | >99.99% | 100% | 100% | - | - | 97.8% | 99.4% | 93.7% | 99.8% | 99.5% | >99.9% | 97.6% | >99.9% | 99.5% | >99.9% | 97.6% | >99.9% | 94.1% | >99% | 91% | >99.99% | 94.1% | >99% | 91% | >99.99% |
| Trisomy 13 (Patau Syndrome) | 1:16,000 | 100% | 99.99% | 73.3% | >99.99% | 100% | 99.99% | - | - | 97.8% | 99.4% | 93.7% | 99.8% | >99.9% | >99.9% | 73.3% | >99.9% | >99.9% | >99.9% | 73.3% | >99.9% | >99% | >99% | 68% | >99.99% | >99% | >99% | 68% | >99.99% |
| Trisomy 15 | 1:100,000,000 | - | - | - | - | - | - | - | - | 97.8% | 99.4% | 93.7% | 99.8% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Trisomy 16 | 1:50,000 | - | - | - | - | - | - | - | - | 97.8% | 99.4% | 93.7% | 99.8% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Trisomy 22 | 1:50,000 | - | - | - | - | - | - | - | - | 97.8% | 99.4% | 93.7% | 99.8% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Sex Chromosome Aneuploidies | |||||||||||||||||||||||||||||
| Turner Syndrome (45,X) | 1:2,500 | 98.11% | 99.98% | 80% | 100% | - | - | - | - | 97.8% | 99.4% | 93.7% | 99.8% | 97.3% | 99.9% | 42% | >99.9% | 97.3% | 99.9% | 42% | >99.9% | >99% | >99% | 7.5% | >99.99% | >99% | >99% | 7.5% | >99.99% |
| Klinefelter Syndrome (47,XXY) | 1:650 | 100% | 100% | 100% | 100% | - | - | - | - | 97.8% | 99.4% | 93.7% | 99.8% | N/a | N/a | N/a | N/a | N/a | N/a | N/a | N/a | >99% | >99% | 7.5% | >99.99% | >99% | >99% | 7.5% | >99.99% |
| Triple X Syndrome (47,XXX) | 1:1,000 | 100% | 99.99% | 94.44% | 100% | - | - | - | - | 97.8% | 99.4% | 93.7% | 99.8% | N/a | N/a | N/a | N/a | N/a | N/a | N/a | N/a | >99% | >99% | 7.5% | >99.99% | >99% | >99% | 7.5% | >99.99% |
| Jacob's Syndrome (47,XYY) | 1:1,000 | 100% | 99.99% | 96.30% | 100% | - | - | - | - | 97.8% | 99.4% | 93.7% | 99.8% | N/a | N/a | N/a | N/a | N/a | N/a | N/a | N/a | >99% | >99% | 7.5% | >99.99% | >99% | >99% | 7.5% | >99.99% |
| Microdeletions | |||||||||||||||||||||||||||||
| DiGeorge Syndrome | 1:4,000 | 83.33% | 99.99% | 71.43% | 100% | - | - | - | - | >99.9% | >99.9% | >99.9% | >99.9% | 97.3% | 99.9% | N/a | N/a | >95% | >99.9% | N/a | N/a | >83.3% | >99% | 53% | >99.99% | 83.3% | >99% | 53% | >99.99% |
| 1p36 deletion syndrome | 1:5,000 | 83.33% | 99.99% | 71.43% | 100% | - | - | - | - | >99.9% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | 99.9% | >99% | 7-17% | >99.99% |
| Angelman syndrome | 1:15,000 | 83.33% | 99.99% | 71.43% | 100% | - | - | - | - | >99.9% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | 95.5% | >99% | 10% | >99.99% |
| Cri-du-chat syndrome | 1:30,000 | 83.33% | 99.99% | 71.43% | 100% | - | - | - | - | >99.9% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | >99% | >99% | 2-5% | >99.99% |
| Prader-Willi syndrome | 1:22,500 | 83.33% | 99.99% | 71.43% | 100% | - | - | - | - | >99.9% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | 93.8% | >99% | 5% | >99.99% |
| Wolf-Hirschhorn Syndrome | 1:50,000 | 83.33% | 99.99% | 71.43% | 100% | - | - | - | - | >99.9% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Jacobsen Syndrome | 1:100,000 | 83.33% | 99.99% | 71.43% | 100% | - | - | - | - | >99.9% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Langer-Giedion Syndrome | 1:1,000,000 | 83.33% | 99.99% | 71.43% | 100% | - | - | - | - | >99.9% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Smith-Magenis Syndrome | 1:25,000 | 83.33% | 99.99% | 71.43% | 100% | - | - | - | - | >99.9% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 9p Deletion Syndrome | 1:>1,000,000 | - | - | - | - | - | - | - | - | >99.9% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 18p Deletion Syndrome | N/a | - | - | - | - | - | - | - | - | >99.9% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 18q22q23 Deletion Syndrome | N/a | - | - | - | - | - | - | - | - | >99.9% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| De Novo/Inherited Monogenic Disorders Part 1 | |||||||||||||||||||||||||||||
| Noonan Syndrome | 4-10:10,000 | N/a | N/a | N/a | N/a | - | - | - | - | 95.82% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cornelia de Lange Syndrome | 1-10:100,000 | N/a | N/a | N/a | N/a | - | - | - | - | 94.72% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Osteogenesis Imperfecta | 5-7:100,000 | N/a | N/a | N/a | N/a | - | - | - | - | 94.9% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Stickler Syndrome | 1:10,000 | N/a | N/a | N/a | N/a | - | - | - | - | 99% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Rett Syndrome | 4-10:100,000 | N/a | N/a | N/a | N/a | - | - | - | - | 89.5% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Achondroplasia | 1-2:10,000 | N/a | N/a | N/a | N/a | - | - | - | - | 98.2% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Crouzon/Pfeiffer Syndrome | 1-9:100,000 | N/a | N/a | N/a | N/a | - | - | - | - | 99% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cleidocranial Dysplasia | 1-2:100,000 | N/a | N/a | N/a | N/a | - | - | - | - | 75.5% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| CHARGE Syndrome | 6-12:100,000 | N/a | N/a | N/a | N/a | - | - | - | - | 98% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cardiofaciocutaneous Syndrome | 4-10:10,000 | N/a | N/a | N/a | N/a | - | - | - | - | 98% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Bohring-Opitz Syndrome | <1:1,000,000 | N/a | N/a | N/a | N/a | - | - | - | - | 82% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Sotos Syndrome | 7-8:100,000 | N/a | N/a | N/a | N/a | - | - | - | - | 43.7% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| De Novo/Inherited Monogenic Disorders Part 2 | |||||||||||||||||||||||||||||
| Alagille Syndrome | 1-3.3:100,000 | N/a | N/a | N/a | N/a | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Schinzel-Giedion Syndrome | 1:>1,000,000 | N/a | N/a | N/a | N/a | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Holoprosencephaly | 1:16,000 | N/a | N/a | N/a | N/a | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Tuberous Sclerosis (TSC1) | 1-2:10,000 | - | - | - | - | - | - | - | - | 94% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Tuberous Sclerosis (TSC2) | <1:1,000,000 | - | - | - | - | - | - | - | - | 94% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Craniosynostosis (TWIST1) | 2-4:100,000 | - | - | - | - | - | - | - | - | 50.3% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Craniosynostosis (EFNB1) | N/a | - | - | - | - | - | - | - | - | 94% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Craniosynostosis (ERF) | N/a | - | - | - | - | - | - | - | - | 93.6% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Craniosynostosis (TCF12) | N/a | - | - | - | - | - | - | - | - | 93% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Kabuki Syndrome | 1:1,900,000 | - | - | - | - | - | - | - | - | 98.3% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Smith-Lemli-Opitz (CDKL5) | 1:50,000 | - | - | - | - | - | - | - | - | 79% | >99.9% | >99.9% | >99.9% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Carrier Screening (Mother + Fetal Risk) | |||||||||||||||||||||||||||||
| Cystic Fibrosis | N/a | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 96% | 95.23% | 50% | 99.79% | - | - | - | - | - | - | - | - |
| Spinal Muscular Atrophy | N/a | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 96% | 95.23% | 50% | 99.79% | - | - | - | - | - | - | - | - |
| Sickle Cell Disease | N/a | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 96% | 95.23% | 50% | 99.79% | - | - | - | - | - | - | - | - |
| Alpha-thalassemia | N/a | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 96% | 95.23% | 50% | 99.79% | - | - | - | - | - | - | - | - |
| Carrier Screening (Mother + Partner Risk) | |||||||||||||||||||||||||||||
| Cystic Fibrosis | - | ✗ | ✗ | ✗ | ✗ | ✓ | ✗ | ✗ | |||||||||||||||||||||
| Spinal Muscular Atrophy | - | ✗ | ✗ | ✗ | ✗ | ✓ | ✗ | ✗ | |||||||||||||||||||||
| Sickle Cell Disease | - | ✗ | ✗ | ✗ | ✗ | ✓ | ✗ | ✗ | |||||||||||||||||||||
| Alpha-thalassemia | - | ✗ | ✗ | ✗ | ✗ | ✓ | ✗ | ✗ | |||||||||||||||||||||
| Fetal Risk Assessment (if mother is carrier) | - | ✗ | ✗ | ✗ | ✗ | ✓ | ✗ | ✗ | |||||||||||||||||||||
| Test Features & Compatibility | |||||||||||||||||||||||||||||
| Triploidy | - | ✗ | ✗ | ✗ | ✗ | ✗ | ✓ | ✗ | |||||||||||||||||||||
| Number of Noonan Syndrome variants | - | 8 | - | 13 | - | - | ✓ | - | |||||||||||||||||||||
| De Novo Genetic Syndromes | - | 25 | - | 52 | - | - | ✓ | - | |||||||||||||||||||||
| Egg Donor Pregnancies | - | ✓ | ✗ | ✗ | ✗ | ✗ | ✓ | ✓ | |||||||||||||||||||||
| Vanishing Twin (after 5 weeks of discovery) | - | ✓ | ✗ | ✗ | ✗ | ✗ | ✓ | ✓ | |||||||||||||||||||||
| Twin Pregnancies | - | ✓ | ✓ | ✗ | ✓ | ✓ | ✓ | ✓ | |||||||||||||||||||||
| Pricing & Turnaround Time | |||||||||||||||||||||||||||||
| Test Price | - | £1,490 | £540 | £990 | £490 | £990 | £590 | £790 | |||||||||||||||||||||
| Turnaround Time (working days) | - | 10-22 | 2-5 | 7-10 | 5-7 | 7-22 | 7-10 | 7-10 | |||||||||||||||||||||
Disclaimer! All statistics mentioned are based on data from the laboratory's Performance and Clinical Validation studies, conducted with pregnant participants. These figures reflect outcomes observed within those specific study groups and may not represent the general population.
Sensitivity and specificity help you understand how reliable a test is. A test with high sensitivity catches more true positives, and one with high specificity avoids false alarms. Together, they help ensure your results are trustworthy.
Not quite. Even highly accurate tests need interpretation. A genetic counsellor helps explain what your result means for you and your family — and whether you need any follow-up or additional screening.
These metrics help determine a test's accuracy. High sensitivity ensures most carriers are identified, while high specificity ensures non-carriers aren't misdiagnosed. Together, they provide a comprehensive view of a test's reliability.
Sensitivity measures how well a test identifies true positives among all who have the condition, while PPV assesses the likelihood that a positive test result is a true positive. Sensitivity is intrinsic to the test, whereas PPV is influenced by the condition's prevalence in the population.
Several things can influence test accuracy — including how common the gene variant is in the population (prevalence), the quality of the lab, and even how the sample was collected. That’s why expert-designed tests and genetic counselling matter.
Test stats like sensitivity or PPV can change based on the population being tested, the condition being looked for, and how the test is used. That’s why context matters — Jeen’s team explains your results in a way that fits your unique case.
Yes. A test designed to catch all potential cases (high sensitivity) might also capture individuals without the condition, leading to false positives and thus lower specificity. Balancing both metrics is crucial for accurate testing.
Yes – and it’s a key part of your journey with Jeen. Our genetic counsellors are here to help you understand what your results mean and guide you through everything, including terms like sensitivity and specificity. You’ll have a counselling session before your test to explain what we’re looking for and what the results could mean. If your result shows something unusual, we’ll contact you and arrange a follow-up session. Even if your results are normal, you're always welcome to book another session if you'd like to talk them through with our team.
Our team of expert Genetic Counsellors is here to help. Whether you're curious about testing, your results, or what’s right for you — we're just a message away.
